Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Short-term Investments: 2022-2025

Historic Short-term Investments for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to $408.3 million.

  • Day One Biopharmaceuticals' Short-term Investments rose 201.07% to $408.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $408.3 million, marking a year-over-year increase of 201.07%. This contributed to the annual value of $406.8 million for FY2024, which is 200.05% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Short-term Investments of $408.3 million as of Q3 2025, which was down 2.20% from $417.5 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Short-term Investments registered a high of $439.7 million during Q1 2025, and its lowest value of $47.6 million during Q1 2024.
  • For the 3-year period, Day One Biopharmaceuticals' Short-term Investments averaged around $254.6 million, with its median value being $253.7 million (2023).
  • In the last 5 years, Day One Biopharmaceuticals' Short-term Investments plummeted by 82.32% in 2024 and then soared by 824.57% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Short-term Investments (Quarterly) stood at $257.0 million in 2022, then tumbled by 47.25% to $135.6 million in 2023, then soared by 200.05% to $406.8 million in 2024, then spiked by 201.07% to $408.3 million in 2025.
  • Its Short-term Investments was $408.3 million in Q3 2025, compared to $417.5 million in Q2 2025 and $439.7 million in Q1 2025.